Skip to main content

Table 3 Exploratory subgroup analysis of progression-free survival (n = 61)

From: Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

   N PFS (months) Ratio (CI) P HR (CI)
Gender Female 49 13.2 1.56 (1.101–2.023) 0.447 0.719 (0.305–1.696)
Male 12 8.45
Age ≤70 31 11.7 0.76 (0.225–1.294) 0.164 1.561 (0.834–2.922)
> 70 30 15.4
Smoking Never 41 15.4 0.545 (0.018–1.073) 0.045 2.118 (1.016–4.418)
Ever 20 8.4
Mutation Exon 19 37 13 0.79 (0.266–1.320) 0.607 1.186 (0.627–2.243)
Exon 21 24 16.4
ECOG 0 24 18.9   0.017  
1 31 12.6
2 6 4.4
Stagea M1a 31 18.9 2.22 (1.708–2.739) 0.002 0.334 (0.167–0.672)
M1b 24 8.5
  1. a6 IIIb stage patients were excluded from this analysis